$Cellular bases of hypofractionated radiotherapy protocols for lung cancer$

Cellular bases of hypofractionated radiotherapy protocols for lung cancer

Abstract The extreme demand on health systems due to the COVID-19 pandemic has led to reconsider hypofractionation. Although the best clinical efficacy of these schemes is being demonstrated, the biological bases have not been established. Thus, after validating basic clinical parameters, through co...

Full description

Bibliographic Details
Main Authors:	ELIANA EVELINA OCOLOTOBICHE, YULIANA CATALINA BANEGAS, GUSTAVO FERRARIS, MARCELO MARTÍNEZ, ALBA MABEL GÜERCI
Format:	Article
Language:	English
Published:	Academia Brasileira de Ciências 2022-07-01
Series:	Anais da Academia Brasileira de Ciências
Subjects:	radiotherapy dose hypofractionation 4Rs Linear-Quadratic Model cytotoxic effect stereotactic body radiotherapy
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652022000600601&tlng=en

Similar Items

Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation
by: Laurence Mengue, et al.
Published: (2020-04-01)

Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
by: Jiang Xue-song, et al.
Published: (2012-03-01)

Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases
by: Xue-Yi Xie, et al.
Published: (2022-07-01)

Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity
by: Crosby Rock, et al.
Published: (2023-08-01)

Hypofractionation in Glioblastoma: An Overview of Palliative, Definitive, and Exploratory Uses
by: Cecilia Jiang, et al.
Published: (2023-11-01)

Clinical outcomes of Hypofractionated stereotactic radiotherapy (HFSRT) among patients with brain metastases in a tertiary medical center in the Philippines
by: Jo-Celine Leong, et al.
Published: (2022-12-01)

Normofractionated stereotactic radiotherapy versus CyberKnife-based hypofractionation in skull base meningioma: a German and Italian pooled cohort analysis
by: Conti Alfredo, et al.
Published: (2019-11-01)

Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk
by: Marcin Miszczyk, et al.
Published: (2022-09-01)

Hypofractionated Radiotherapy in Localized, Low–Intermediate-Risk Prostate Cancer: Current and Future Prospectives
by: Maria Chiara Lo Greco, et al.
Published: (2023-06-01)

Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
by: Christine Kornhuber, et al.
Published: (2023-05-01)

Hypofractionated Radiotherapy for Hematologic Malignancies during the COVID-19 Pandemic and Beyond
by: Febin Antony, et al.
Published: (2024-01-01)

The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases
by: Tyler Gutschenritter, et al.
Published: (2020-12-01)

Recent Advances in Radiotherapy Modalities for Prostate Cancer
by: Jure Murgić, et al.
Published: (2022-01-01)

Conventional versus different hypofractionated radiotherapy dosage schedules in postmastectomy advanced breast cancer
by: Neeraj Jain, et al.
Published: (2022-01-01)

Hypofractionated Radiotherapy for Post-Operative Breast Cancer Patients at Delta Hospital - an Evaluation of Clinical Experience
by: Parvin Akhter Banu, et al.
Published: (2015-01-01)

Hypofractionated Radiotherapy in African Cancer Centers
by: William Swanson, et al.
Published: (2021-02-01)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
by: Lee Dong, et al.
Published: (2012-06-01)

Acute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort
by: Marie Bruand, et al.
Published: (2022-12-01)

A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol
by: Yun Guan, et al.
Published: (2022-07-01)

Accelerated Hypofractionated Whole Breast Radiotherapy for Early Breast Cancer; A Randomized Phase III Clinical Trial
by: Sare Hosseini, et al.
Published: (2020-05-01)

A Study of Volumetric Variation in the Excision Cavity during Hypofractionated Whole Breast Radiotherapy
by: Ayatallah Youssief Mohammed, et al.
Published: (2023-04-01)

Indications, feasibility, safety, and efficacy of CyberKnife radiotherapy for the treatment of olfactory groove meningiomas: a single institutional retrospective series
by: Jianmin Liu, et al.
Published: (2020-03-01)

Dosimetric Parameters in Hypofractionated Stereotactic Radiotherapy for Brain Metastases: Do Flattening Filter-Free Beams Bring Benefits? A Preliminary Study
by: Diana M. Ghemiș, et al.
Published: (2023-01-01)

Hypofractionated Radiation Therapy for Large Brain Metastases
by: Giuseppina Laura Masucci
Published: (2018-10-01)

Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?
by: Sean Mahase, et al.
Published: (2020-12-01)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
by: Georges Noël, et al.
Published: (2013-09-01)

Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report
by: Yun Guan, et al.
Published: (2022-04-01)

Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review
by: Siyer Roohani, et al.
Published: (2022-09-01)

A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial
by: Julian Biau, et al.
Published: (2020-08-01)

Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions
by: Huayong Jiang, et al.
Published: (2021-12-01)

The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft Tissue Sarcomas
by: Mateusz Jacek Spałek, et al.
Published: (2021-03-01)

Efficacy and Toxicity of Hypofractionated Palliative Radiotherapy for Breast Cancer Patients with Skin Invasion
by: Talha Maqsood, et al.
Published: (2023-08-01)

Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review
by: Lei Liu, et al.
Published: (2020-01-01)

Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer
by: Katrina Woodford, et al.
Published: (2017-10-01)

Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: Toxicity analysis
by: Dong-Yun Kim, et al.
Published: (2021-02-01)

Hypofractionation: The standard for external beam breast irradiation
by: Adrian Murray Brunt, et al.
Published: (2023-06-01)

FLASH Radiotherapy Using Single-Energy Proton PBS Transmission Beams for Hypofractionation Liver Cancer: Dose and Dose Rate Quantification
by: Shouyi Wei, et al.
Published: (2022-01-01)

A Systematic Review on the Impact of Hypofractionated and Stereotactic Radiotherapy on Immune Cell Subpopulations in Cancer Patients
by: Silvia Takanen, et al.
Published: (2022-10-01)

Symptom palliation of hypofractionated radiotherapy for patients with incurable inflammatory breast cancer
by: Hoon Sik Choi, et al.
Published: (2019-06-01)

Isoeffect calculations with the linear quadratic and its extensions: An examination of model-dependent estimates at doses relevant to hypofractionation
by: Frederick W McKenna, et al.
Published: (2011-01-01)